These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12915429)

  • 1. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.
    Szapary PO; Wolfe ML; Bloedon LT; Cucchiara AJ; DerMarderosian AH; Cirigliano MD; Rader DJ
    JAMA; 2003 Aug; 290(6):765-72. PubMed ID: 12915429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study.
    Nohr LA; Rasmussen LB; Straand J
    Complement Ther Med; 2009 Jan; 17(1):16-22. PubMed ID: 19114224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration.
    Ulbricht C; Basch E; Szapary P; Hammerness P; Axentsev S; Boon H; Kroll D; Garraway L; Vora M; Woods J;
    Complement Ther Med; 2005 Dec; 13(4):279-90. PubMed ID: 16338199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia.
    Singh RB; Niaz MA; Ghosh S
    Cardiovasc Drugs Ther; 1994 Aug; 8(4):659-64. PubMed ID: 7848901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
    Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
    JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guggulipid and cholesterol levels.
    Firenzuoli F; Gori L
    JAMA; 2003 Dec; 290(21):2800; author reply 2801. PubMed ID: 14657061
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial.
    Maron DJ; Lu GP; Cai NS; Wu ZG; Li YH; Chen H; Zhu JQ; Jin XJ; Wouters BC; Zhao J
    Arch Intern Med; 2003 Jun; 163(12):1448-53. PubMed ID: 12824094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
    Davidson MH; Donovan JM; Misir S; Jones MR
    Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of NC120 for Improving Lipid Profile: A Double Blind Randomized Controlled Trial.
    Nafrialdi N; Hudyono J; Suyatna FD; Setiawati A
    Acta Med Indones; 2019 Jan; 51(1):19-25. PubMed ID: 31073102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guggulu and Triphala for the Treatment of Hypercholesterolaemia: A Placebo-Controlled, Double-Blind, Randomised Trial.
    Donato F; Raffetti E; Toninelli G; Festa A; Scarcella C; Castellano M;
    Complement Med Res; 2021; 28(3):216-225. PubMed ID: 33242870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
    J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: a randomized placebo-controlled trial.
    Berthold HK; Schulte DM; Lapointe JF; Lemieux P; Krone W; Gouni-Berthold I
    J Dairy Sci; 2011 Feb; 94(2):589-601. PubMed ID: 21257028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of a nutraceutical combination of red yeast rice, guggulipid, and chromium picolinate evaluated in a randomized, placebo-controlled, double-blind study.
    Iskandar I; Harahap Y; Wijayanti TR; Sandra M; Prasaja B; Cahyaningsih P
    Complement Ther Med; 2020 Jan; 48():102282. PubMed ID: 31987238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
    Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.